{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for methylprednisolone root_Display\ Name in Display Name (approximate match)
Status:
US Approved Rx
(2004)
Source:
ANDA040612
(2004)
Source URL:
First approved in 1957
Source:
NDA011153
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Methylprednisolone is a prednisolone derivative with similar anti-inflammatory and immunosuppressive action. It is adjunctive therapy for short-term administration in rheumatoid arthritis. It is indicated in the following conditions: endocrine disorders, rheumatic disorders, collagen diseases, allergic states etc. Methylprednisolone is marketed in the USA and Canada under the brand names Medrol and Solu-Medrol. Methylprednisolone is a GR receptor agonist.
Status:
Investigational
Source:
USAN:ULODESINE SUCCINATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
USAN:ZICRONAPINE SUCCINATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03283059: Phase 3 Interventional Unknown status Alzheimer Disease
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
![Structure of 1,4-diethyl 2-[(4-sulphophenyl)hydrazono]succinate](/img/cf5c4c8d-624b-4d61-ada7-5c16064f831f.svg?size=200&context=icibstnzri)
